Eli Lilly‘s net income was $1.197bn, compared to $1.348bn for the same period in the prior year.
The company’s operating income was $1.588bn for the second quarter ended 30 June 2011, as compared to $1.754bn for the same period in 2010.
For the six months ended 30 June 2011 total revenue were $12.092bn, compared to $11.234bn for the same period in 2010.
Net income was $2.253bn for the six months ended 30 June 2011, as compared to $2.597bn for the same period prior year.
For the six months ended 30 June 2011, the company’s operating income were $2.874bn , as compared to $3.388bn for the same period in 2010.
Eli Lilly chairman, president and CEO John Lechleiter said they are investing for the company’s future by supporting the launches of new medicines and new indications, as well as funding their R&D pipeline, which now boasts 70 potential new medicines in clinical development.